Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2020

View Archived Issues

Metformin, explained

Autolus presents phase I data from Amelia study of AUTO-3 in pediatric patients

Phase I data presented for ambrisentan in sickle cell disease

PGC-1alpha as a novel therapeutic target in sickle cell disease

CD137 deficiency linked to susceptibility to EBV-associated lymphoma

Repotrectinib reduces tumor growth of ALK-driven neuroblastoma

Spot on: Breaching all three meninges improves drug delivery to brain

Ono presents phase II data for tirabrutinib in relapsed/refractory Waldenstrom's macroglobulinemia

Herantis advances xCDNF program into lead optimization

China NMPA approves Cecolin HPV16/18 vaccine

Amgen patents KRAS mutant inhibitors

New compounds for hepatitis B virus presented by VenatoRx Pharmaceuticals

Ryvu Therapeutics identifies hSTING receptor agonists

Pfizer divulges new GLP-1R agonists

Roche identifies new TLR7/8/9 antagonists

Regeneron begins open-label extension study with REGN-3918 in PNH

Genmab studies GEN-1042 safety for malignant solid tumors in phase I/IIa trial

Roche starts phase I study of RO-7296682 in advanced solid tumors

GSK initiates phase III study of belantamab mafodotin for newly diagnosed multiple myeloma

U.S. researchers present novel coagulation factor VIIa chimera for hemophilia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...